Caris Life Sciences launches AI-powered PDAC signature using WES/WTS and 550,000-patient data
Caris Life Sciences launched a proprietary AI Insights signature for pancreatic ductal adenocarcinoma, integrating WES and WTS data in its Molecular Tumor Board Report to guide first-line FOLFIRINOX vs gem/nab-p therapy selection. The engine leverages over 550,000-patient real-world datasets to categorize risk and recommend de-escalation or intensified regimens.
1. Signature Launch and Report Integration
Caris introduced a novel AI Insights signature for pancreatic ductal adenocarcinoma within its Molecular Tumor Board Report, available to existing customers without additional tissue sampling when ordering MI Cancer Seek.
2. Advanced Multimodal AI Platform
The CodeAI platform integrates Whole Exome and Whole Transcriptome Sequencing with clinical data from over 550,000 patients to identify molecular patterns guiding biomarker discovery and treatment insights.
3. Personalized First-Line Treatment Guidance
The PDAC signature provides high- and standard-risk categorizations and therapy recommendations between FOLFIRINOX and gemcitabine/nab-paclitaxel using Kaplan-Meier matching to improve regimen selection and potential de-escalation.
4. Regulatory Milestones and Future Research
Caris received FDA approval in November 2024 for its combined WES/WTS assay and plans a publication to demonstrate the signature's ability to identify patients for treatment intensification or de-escalation.